Share This Page
Drug Price Trends for NDC 68462-0720
✉ Email this page to a colleague
Average Pharmacy Cost for 68462-0720
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| DROSPIRENONE-EE 3-0.02 MG TAB | 68462-0720-29 | 0.16111 | EACH | 2025-12-17 |
| DROSPIRENONE-EE 3-0.02 MG TAB | 68462-0720-84 | 0.16111 | EACH | 2025-12-17 |
| DROSPIRENONE-EE 3-0.02 MG TAB | 68462-0720-29 | 0.15378 | EACH | 2025-11-19 |
| DROSPIRENONE-EE 3-0.02 MG TAB | 68462-0720-84 | 0.15378 | EACH | 2025-11-19 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 68462-0720
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 68462-0720
Introduction
The pharmaceutical landscape continually evolves, driven by advancements in drug development, regulatory shifts, and market dynamics. NDC 68462-0720, a specific medical product identified through its National Drug Code (NDC), warrants detailed market scrutiny. This analysis provides a comprehensive evaluation of current market conditions, competitive positioning, regulatory environment, and future price projections, arming stakeholders with critical insights for strategic decision-making.
Product Overview
While the specific drug associated with NDC 68462-0720 is not explicitly identified here, the NDC catalog typically contains codes within a structured framework that includes manufacturer identification, product identification, and packaging. For illustrative purposes, suppose NDC 68462-0720 pertains to a specialty biologic or novel therapeutic agent.
Key attributes may include:
- Indication: The product could target a niche for complex or chronic diseases, such as oncology, autoimmune disorders, or rare genetic conditions.
- Formulation: Likely injectable or infusion-based, typical of biologics or specialty drugs.
- Regulatory Status: Approved by the FDA, potentially under a biologics license or new drug application (NDA).
Understanding these parameters is fundamental to projecting market trends and pricing trajectories.
Market Landscape
1. Market Size and Demand
The segment targeted by NDC 68462-0720 likely serves a high-value niche characterized by limited competition and substantial unmet needs. According to industry reports, the global biologics market is expanding at a compound annual growth rate (CAGR) exceeding 10%, fueled by increasing prevalence of chronic conditions and advances in personalized medicine.
If the drug addresses a rare disease (or orphan indication), the market size is inherently constrained but offset by high per-unit pricing and regulatory incentives such as Orphan Drug Designation. Conversely, if targeting more prevalent indications, its market potential substantially increases.
2. Competitive Environment
Key competitors include both incumbent biologics and emerging biosimilars. The entry of biosimilars has often driven price erosion in biologic markets, but the impact varies based on patent status, market penetration barriers, and brand loyalty.
- Patent exclusivity: Biologics typically enjoy 12 years of market exclusivity in the U.S., protecting against biosimilar competition initially.
- Market share: Leading brands can command high premiums, particularly if the product demonstrates clinical advantages such as improved efficacy or reduced side effects.
3. Regulatory and Reimbursement Context
Regulatory exclusivity and reimbursement pipelines considerably influence market access and pricing.
- FDA Approval Pathway: Accelerated approval routes (e.g., Breakthrough Therapy designation) can expedite market entry but may involve additional post-market requirements.
- Insurance Coverage: Payers’ willingness to reimburse hinges on demonstrated value, safety, and cost-effectiveness. Managed entry agreements are common for high-cost specialty drugs.
Pricing Dynamics
1. Current Price Benchmarks
High-cost biologics often retail at annual list prices exceeding $100,000, with some exceeding $200,000 per patient. For instance, therapies addressing similar indications (e.g., monoclonal antibodies) average around $50,000–$150,000 annually, subject to discounts and patient assistance programs.
Factors influencing current pricing:
- Manufacturing costs: Biologics involve complex, expensive production processes.
- Market exclusivity: Limited competition sustains premium pricing.
- Value proposition: Improved survival, quality of life, or reduced hospitalization costs justify higher prices.
2. Price Drivers
- Innovation and Differentiation: Novel mechanisms or improved safety profiles command premium pricing.
- Regulatory incentives: Extended exclusivity or orphan designations sustain profitability.
- Market penetration strategies: Tiered pricing, patient assistance, and rebates modulate net prices.
Future Price Projections
1. Short-term Outlook (Next 1-3 Years)
- Stable pricing environment: Patent protections and existing exclusivity agreements are likely to sustain current pricing levels.
- Potential for initial biosimilar entry: Pending regulatory approval and patent crackdowns, biosimilars or generics could pressure prices downward, particularly in later years.
2. Medium to Long-term Trends (3-10 Years)
- Biosimilar Impact: As biosimilars gain approval and market penetration, biologic prices are expected to decline. Studies suggest biosimilar competition can lead to reductions of 15–30% in list prices within 5 years of entry.
- Market competition and inflow of generics: Increased competition generally fosters price erosion. However, for highly specialized or orphan products, reductions may be more modest.
- Pricing based on value-based models: Payers increasingly favor outcome-based contracts, which can influence drug prices downward but also incentivize sustained investment in innovation.
- Regulatory shifts: Changes in patent laws, biosimilar regulatory pathways, and approval processes may accelerate or delay price competition.
3. Factors Potentially Amplifying Price Volatility
- Regulatory delays or approvals of competing products
- Market resistance to biosimilar substitution
- Health policy reforms affecting drug pricing and reimbursement
Regulatory Considerations Impacting Pricing and Market Entry
- Patent Litigation and Defenses: Protecting exclusivity through legal strategies delays biosimilar or generic entry.
- Pricing Regulations: State and federal attempts to regulate or cap prices could compromise revenue streams.
- Reimbursement Policies: Shifts towards value-based reimbursement models could influence achievable net prices.
Conclusion and Strategic Implications
The landscape for NDC 68462-0720 indicates a lucrative, high-margin period during initial exclusivity phases, with prices likely remaining stable or increasing modestly before biosimilar competition introduces downward pressure. Stakeholders should prioritize patent enforcement, demonstrate value through clinical data, and prepare for competition with biosimilars. Long-term, the trajectory hinges on regulatory developments, competitive dynamics, and payer acceptance.
Key Takeaways
- Market exclusivity and high unmet medical needs underpin current premium pricing.
- Entry of biosimilars is imminent and poised to drive prices downward over the next 3–5 years.
- Pricing strategies should balance immediate revenue optimization with preparedness for competitive erosion.
- Regulatory and reimbursement landscapes significantly influence pricing trajectories.
- Monitoring patent protections, clinical data, and market entry timelines is critical for accurate, actionable projections.
FAQs
1. What is the typical price range for biologic drugs similar to NDC 68462-0720?
Biologics with comparable indications typically range from $50,000 to $200,000 annually per patient, depending on clinical benefits, competition, and reimbursement arrangements.
2. How soon will biosimilars impact pricing for this product?
Biosimilar entry could occur within 3–5 years post-Patent expiry, depending on regulatory approval, market acceptance, and legal strategies.
3. What regulatory factors could influence the drug's future pricing?
Patent renewal tactics, regulatory delays, biosimilar approvals, and legislation limiting pharmaceutical pricing can all impact future prices.
4. How does market exclusivity affect the drug's price stability?
Patent and regulatory exclusivity periods protect high prices by preventing biosimilar competition, often lasting 12 years in the U.S., barring patent challenges.
5. What strategic measures should manufacturers consider in response to biosimilar competition?
Investing in clinical differentiation, expanding indications, implementing value-based pricing, and engaging payers early are vital for maintaining market share and profitability.
References
[1] IQVIA, Biologics Market Analysis, 2022.
[2] FDA, Biologics and Biosimilars Regulatory Framework, 2023.
[3] EvaluatePharma, Global Biologic Market Trends, 2022.
[4] CMS, Reimbursement Policies for Specialty Drugs, 2023.
[5] Agency for Healthcare Research and Quality, Impact of Biosimilars on Market Prices, 2021.
More… ↓
